vTv Therapeutics (VTVT) Shares Down 3.4%

vTv Therapeutics (NASDAQ:VTVT) shares dropped 3.4% during mid-day trading on Monday . The company traded as low as $1.67 and last traded at $1.68. Approximately 2,000 shares traded hands during trading, a decline of 100% from the average daily volume of 1,221,593 shares. The stock had previously closed at $1.74.

VTVT has been the subject of a number of analyst reports. Zacks Investment Research upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, April 13th. Northland Securities lowered vTv Therapeutics from an “outperform” rating to a “market perform” rating and set a $28.00 price target for the company. in a research report on Tuesday, April 10th. Roth Capital lowered vTv Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $18.00 to $17.00 in a research report on Tuesday, April 10th. ValuEngine upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Seaport Global Securities initiated coverage on vTv Therapeutics in a research report on Thursday, March 29th. They set a “buy” rating and a $14.00 price target for the company. Eight equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $13.69.

The company has a quick ratio of 0.35, a current ratio of 0.35 and a debt-to-equity ratio of -0.09. The company has a market capitalization of $56.11 million, a P/E ratio of -1.00 and a beta of 1.84.



vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Tuesday, May 15th. The biotechnology company reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.04). The firm had revenue of $2.06 million during the quarter, compared to the consensus estimate of $3.14 million. sell-side analysts anticipate that vTv Therapeutics will post -1.24 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Creative Planning acquired a new stake in shares of vTv Therapeutics during the fourth quarter worth $114,000. Royce & Associates LP acquired a new stake in shares of vTv Therapeutics during the fourth quarter worth $1,352,000. Millennium Management LLC acquired a new stake in shares of vTv Therapeutics during the fourth quarter worth $377,000. C WorldWide Group Holding A S acquired a new stake in shares of vTv Therapeutics during the first quarter worth $399,000. Finally, JPMorgan Chase & Co. raised its position in vTv Therapeutics by 55.9% during the first quarter. JPMorgan Chase & Co. now owns 327,728 shares of the biotechnology company’s stock valued at $1,333,000 after buying an additional 117,513 shares during the period. 15.04% of the stock is currently owned by institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply